Mark Salvati

Mark Salvati is a seasoned professional in the biotechnology and pharmaceutical industries, currently serving as Vice President at Regeneron since March 2022, leading development for the Anti-LAG3 Antibody Fianlimab and Anti-GITR Antibody programs. Prior experience includes the role of Global Product General Manager and Oncology Early Development Lead at Amgen, overseeing the global early development of Immuno-Oncology agents with a focus on CAR-T and T-Cell redirection for solid tumors. Salvati has also held senior leadership positions at Janssen Inc., Bristol-Myers Squibb, and Wyeth, specializing in compound development, clinical research, and medical affairs within the Oncology field. Academic credentials include a Doctor of Philosophy (Ph.D.) in Organic Chemistry from UCLA.